Vaccines

Vaccines are one of the most significant public health achievements of the last century. Their value extends beyond narrow health effects for vaccinated people to generating social and economic benefits.

Yayoi Kusama's infinity mirror rooms at the Tate gallery
News

New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations   

13 October 2025

A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.

Yayoi Kusama's infinity mirror rooms at the Tate gallery
Publication

The broader economic benefits of COVID-19 vaccination 

13 October 2025

Why investigating the economic case for ongoing COVID-19 vaccination matters While public health strategies around COVID-19 have transitioned from a pandemic to an endemic setting, the…

Insights

Prevention pays off – so why aren’t we doing more of it? 

5 June 2025

We know that immunisation pays off: the wider societal benefits of childhood immunisation programmes in low and middle income countries outweigh their costs up to 51 times while…

Insights

OHE submission to the UK Parliamentary Inquiry on an Ageing Society

20 May 2025

OHE’s written submission to parliament focused on raising population health in older age and increasing access to fertility treatments as two possible avenues to address the challenges of demographic change.

Publication

Analysing Global Immunisation Expenditure

15 April 2025

Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases.

Publication

Employer Costs from Respiratory Infections

16 December 2024

Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and address health inequities.

News

Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report

18 April 2024

Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.

Publication

Socio-Economic Value of Adult Immunisation Programmes

18 April 2024

Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.

Event

Valuing Vaccines: The Economics of Vaccines & Immunisations

19 April 2023

On 26th April we will be joined by global experts to discuss the value of equity in access to vaccines worldwide, and hear from practitioners in the economic evaluation of vaccines in resource constrained environments.